Stys, T. P., Gedela, M., Gowda, S. N., Bares, V., Fanta, L., Petrasko, M., . . . Stys, A. T. (2021). CYP2C19 genotype-directed P(2)Y(12) inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention. Indian Heart J.
シカゴスタイル引用形Stys, Tomasz P., Maheedhar Gedela, Smitha N. Gowda, Valerie Bares, Lauren Fanta, Marian Petrasko, Catherine Hajek, Eric Larson, , Adam T. Stys. "CYP2C19 Genotype-directed P(2)Y(12) Inhibitor Antiplatelet Therapy Normalizes Risk for Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention." Indian Heart J 2021.
MLA引用形式Stys, Tomasz P., et al. "CYP2C19 Genotype-directed P(2)Y(12) Inhibitor Antiplatelet Therapy Normalizes Risk for Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention." Indian Heart J 2021.